Phase 3 biotech developing a novel kinase inhibitor for EGFR-mutated lung cancer.
Industry: Health Care
Latest Trade: $27.82 +1.22 (+4.6%)
First Day Return: +11.1%
Return from IPO: +47.8%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/05/2024 |
Offer Price | $18.00 |
Price Range $17.00 - $19.00 | |
Offer Shares (mm) | 9.7 |
Deal Size ($mm) | $175 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/25/2024 |
Offer Price | $18.00 |
Price Range $17.00 - $19.00 | |
Offer Shares (mm) | 9.7 |
Deal Size ($mm) | $175 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Goldman Sachs |
Jefferies |
more |
Company Data | |
---|---|
Headquarters | Newtown Square, PA, United States |
Founded | 2021 |
Employees at IPO | 40 |
Website arrivent.com |